Crossref
Ultragenyx Cuts 20% of Workforce in Restructuring; Sells Rare Pediatric Review Vouchers Totaling $413M
Human Gene Therapy · 21.11.2026
DOI: 10.1177/10430342261509799 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 21.11.2026. Verfasst von Alex Philippidis. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Philippidis, A. (2026). Ultragenyx Cuts 20% of Workforce in Restructuring; Sells Rare Pediatric Review Vouchers Totaling $413M. Human Gene Therapy. https://doi.org/10.1177/10430342261509799
Vancouver
Philippidis A. Ultragenyx Cuts 20% of Workforce in Restructuring; Sells Rare Pediatric Review Vouchers Totaling $413M. Human Gene Therapy. 2026. doi:10.1177/10430342261509799
BibTeX
@article{Philippidis2026,
author = {Philippidis, Alex},
title = {Ultragenyx Cuts 20% of Workforce in Restructuring; Sells Rare Pediatric Review Vouchers Totaling $413M},
journal = {Human Gene Therapy},
year = {2026},
doi = {10.1177/10430342261509799}
}
EUVIMED